JA
Therapeutic Areas
Corvus Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Soquelitinib (CPI-818) | Relapsed/Refractory T Cell Lymphomas (TCL) | Phase 1 |
| Ciforadenant (CPI-444) | Cancer | Phase 1/2 |
| Mupadolimab (CPI-006) | Non-Small Cell Lung Cancer (NSCLC) | Phase 1/2 |
Leadership Team at Corvus Pharmaceuticals
RA
Richard A. Miller, M.D.
President, CEO, and Co-Founder
LL
Leiv Lea
Chief Financial Officer
OA
Otute Akiti, Ph.D.
Vice President, CMC
WB
William Ben Jones, Ph.D.
Senior Vice President, Pharmaceutical Development
GL
Gabriel Luciano
Vice President, Clinical Operations